REDWOOD CITY, Calif., June 13 /PRNewswire-FirstCall/ -- Genitope Corporation (Nasdaq: GTOP - News) today announced that MyVax® personalized immunotherapy received Fast Track designation from the U.S. Food & Drug Administration (FDA) for the treatment of follicular non-Hodgkin’s Lymphoma (fNHL).
